1. Home
  2. CALC vs SPCB Comparison

CALC vs SPCB Comparison

Compare CALC & SPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • SPCB
  • Stock Information
  • Founded
  • CALC 2011
  • SPCB 1988
  • Country
  • CALC United States
  • SPCB Israel
  • Employees
  • CALC 15
  • SPCB N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • SPCB Semiconductors
  • Sector
  • CALC Health Care
  • SPCB Technology
  • Exchange
  • CALC Nasdaq
  • SPCB Nasdaq
  • Market Cap
  • CALC 45.4M
  • SPCB 48.3M
  • IPO Year
  • CALC N/A
  • SPCB N/A
  • Fundamental
  • Price
  • CALC $3.23
  • SPCB $10.53
  • Analyst Decision
  • CALC Strong Buy
  • SPCB Strong Buy
  • Analyst Count
  • CALC 2
  • SPCB 1
  • Target Price
  • CALC $14.50
  • SPCB $18.00
  • AVG Volume (30 Days)
  • CALC 52.6K
  • SPCB 113.6K
  • Earning Date
  • CALC 11-12-2025
  • SPCB 11-13-2025
  • Dividend Yield
  • CALC N/A
  • SPCB N/A
  • EPS Growth
  • CALC N/A
  • SPCB N/A
  • EPS
  • CALC N/A
  • SPCB 0.98
  • Revenue
  • CALC N/A
  • SPCB $27,426,000.00
  • Revenue This Year
  • CALC N/A
  • SPCB N/A
  • Revenue Next Year
  • CALC N/A
  • SPCB $29.31
  • P/E Ratio
  • CALC N/A
  • SPCB $10.77
  • Revenue Growth
  • CALC N/A
  • SPCB 2.17
  • 52 Week Low
  • CALC $1.42
  • SPCB $2.97
  • 52 Week High
  • CALC $5.65
  • SPCB $18.95
  • Technical
  • Relative Strength Index (RSI)
  • CALC 52.57
  • SPCB 46.20
  • Support Level
  • CALC $3.13
  • SPCB $9.71
  • Resistance Level
  • CALC $3.33
  • SPCB $10.95
  • Average True Range (ATR)
  • CALC 0.20
  • SPCB 0.70
  • MACD
  • CALC -0.00
  • SPCB -0.21
  • Stochastic Oscillator
  • CALC 38.24
  • SPCB 23.77

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

Share on Social Networks: